Evidence map›Paper›PMID 37139582›Full record

ArticleCell cycle (Georgetown, Tex.)2023

Seeing is believing: the impact of RB on nuclear organization.

Badri Krishnan, Ioannis Sanidas, Nicholas J Dyson

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell cycle (Georgetown, Tex.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Badri KrishnanMassachusetts General Hospital Cancer Center and Harvard Medical School, Charlestown, MA, USA.
Ioannis SanidasMassachusetts General Hospital Cancer Center and Harvard Medical School, Charlestown, MA, USA.ORCID 0000-0002-9063-6840
Nicholas J DysonMassachusetts General Hospital Cancer Center and Harvard Medical School, Charlestown, MA, USA.
Harvard University · US

Funding

Deciphering the code of RB phosphorylationR01CA236538 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI DYSON, NICHOLAS J · 2018 to 2022
$2.5M
The consequences of RB-lossR01GM117413 · NIGMS · MASSACHUSETTS GENERAL HOSPITAL · PI DYSON, NICHOLAS J · 2016 to 2019
$2.1M
NCI NIH HHS R01 CA236538NIGMS NIH HHS R01 GM117413
6 · The paper itself

Abstract

The retinoblastoma tumor suppressor (RB) prevents G1 to S cell cycle transition by inhibiting E2F activity. This function requires that RB remains un- or underphosphorylated (the so-called active forms of RB). Recently, we showed that active forms of RB cause widespread changes in nuclear architecture that are visible under a microscope. These phenotypes did not correlate with cell cycle arrest or repression of the E2F transcriptional program, but appeared later, and were associated with the appearance of autophagy or in IMR-90 cells with senescence markers. In this perspective, we describe the relative timing of these RB-induced events and discuss the mechanisms that may underlie RB-induced chromatin dispersion. We consider the relationship between RB-induced dispersion, autophagy, and senescence and the potential connection between dispersion and cell cycle exit.

Indexed as

Retinoblastoma ProteinTranscription FactorsCell CycleCell Cycle ProteinsCell DivisionE2F Transcription FactorsCell Cycle ProteinsE2F Transcription FactorsRetinoblastoma ProteinTranscription FactorsautophagyCell cycleretinoblastomasenescence

Identifiers

PMID37139582
PMCPMC10228396
OpenAlexW4368357544

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.